Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101


Risk Factors for Mortality in Children with Acinetobacter baumannii Bacteremia in South Korea: The Role of Carbapenem Resistance.

Choe YJ, Lee HJ, Choi EH.

Microb Drug Resist. 2019 Oct;25(8):1210-1218. doi: 10.1089/mdr.2018.0465. Epub 2019 May 22.


Clinical outcomes of children with carbapenem-resistant Acinetobacter baumannii bacteremia.

Vandepitte WP, Berge J, Andersson R.

J Med Assoc Thai. 2014 Nov;97 Suppl 11:S129-39.


Risk factors for carbapenem non-susceptibility and mortality in Acinetobacter baumannii bacteremia in children.

Punpanich W, Nithitamsakun N, Treeratweeraphong V, Suntarattiwong P.

Int J Infect Dis. 2012 Nov;16(11):e811-5. doi: 10.1016/j.ijid.2012.07.006. Epub 2012 Aug 13.


Early administration of appropriate antimicrobial agents to improve the outcome of carbapenem-resistant Acinetobacter baumannii complex bacteraemic pneumonia.

Park SY, Lee EJ, Kim T, Yu SN, Park KH, Lee MS, Park SY, Jeon MH, Kim TH, Choo EJ.

Int J Antimicrob Agents. 2018 Mar;51(3):407-412. doi: 10.1016/j.ijantimicag.2017.10.018. Epub 2017 Nov 6.


Risk factors for mortality in patients with carbapenem-resistant Acinetobacter baumannii bacteremia: impact of appropriate antimicrobial therapy.

Kim YJ, Kim SI, Hong KW, Kim YR, Park YJ, Kang MW.

J Korean Med Sci. 2012 May;27(5):471-5. doi: 10.3346/jkms.2012.27.5.471. Epub 2012 Apr 25.


Risk factors and clinical outcomes of multidrug-resistant Acinetobacter baumannii bacteremia at a university hospital in Thailand.

Anunnatsiri S, Tonsawan P.

Southeast Asian J Trop Med Public Health. 2011 May;42(3):693-703.


Risk factors for occurrence and 30-day mortality for carbapenem-resistant Acinetobacter baumannii bacteremia in an intensive care unit.

Kim SY, Jung JY, Kang YA, Lim JE, Kim EY, Lee SK, Park SC, Chung KS, Park BH, Kim YS, Kim SK, Chang J, Park MS.

J Korean Med Sci. 2012 Aug;27(8):939-47. doi: 10.3346/jkms.2012.27.8.939. Epub 2012 Jul 25.


Risk Factors for Mortality in Patients with Acinetobacter baumannii Bacteremia.

Park SY, Choo JW, Kwon SH, Yu SN, Lee EJ, Kim TH, Choo EJ, Jeon MH.

Infect Chemother. 2013 Sep;45(3):325-30. doi: 10.3947/ic.2013.45.3.325. Epub 2013 Sep 27.


Clinical and microbiological characterization of carbapenem-resistant Acinetobacter baumannii bloodstream infections.

Song JY, Cheong HJ, Choi WS, Heo JY, Noh JY, Kim WJ.

J Med Microbiol. 2011 May;60(Pt 5):605-11. doi: 10.1099/jmm.0.029439-0. Epub 2011 Jan 13.


The clinical characteristics, carbapenem resistance, and outcome of Acinetobacter bacteremia according to genospecies.

Park KH, Shin JH, Lee SY, Kim SH, Jang MO, Kang SJ, Jung SI, Chung EK, Ko KS, Jang HC.

PLoS One. 2013 Jun 3;8(6):e65026. doi: 10.1371/journal.pone.0065026. Print 2014.


Endemic carbapenem-nonsusceptible Acinetobacter baumannii-calcoaceticus complex in intensive care units of the national referral hospital in Jakarta, Indonesia.

Saharman YR, Karuniawati A, Sedono R, Aditianingsih D, Sudarmono P, Goessens WHF, Klaassen CHW, Verbrugh HA, Severin JA.

Antimicrob Resist Infect Control. 2018 Jan 12;7:5. doi: 10.1186/s13756-017-0296-7. eCollection 2018.


Carbapenem-resistant versus carbapenem-susceptible Acinetobacter baumannii bacteremia in a Greek intensive care unit: risk factors, clinical features and outcomes.

Routsi C, Pratikaki M, Platsouka E, Sotiropoulou C, Nanas S, Markaki V, Vrettou C, Paniara O, Giamarellou H, Roussos C.

Infection. 2010 Jun;38(3):173-80. doi: 10.1007/s15010-010-0008-1. Epub 2010 Mar 12.


Excess Mortality Associated With Colistin-Tigecycline Compared With Colistin-Carbapenem Combination Therapy for Extensively Drug-Resistant Acinetobacter baumannii Bacteremia: A Multicenter Prospective Observational Study.

Cheng A, Chuang YC, Sun HY, Sheng WH, Yang CJ, Liao CH, Hsueh PR, Yang JL, Shen NJ, Wang JT, Hung CC, Chen YC, Chang SC.

Crit Care Med. 2015 Jun;43(6):1194-204. doi: 10.1097/CCM.0000000000000933.


Natural prognosis of carbapenem-resistant Acinetobacter baumannii bacteremia in patients who did not receive appropriate antibiotic treatment: A retrospective multicenter study in Korea.

Kim T, Lee EJ, Park SY, Yu SN, Lee YM, Park KH, Park SY, Jeon MH, Choo EJ, Kim TH, Lee MS.

Medicine (Baltimore). 2018 Oct;97(43):e12984. doi: 10.1097/MD.0000000000012984.


Risk Factors and Clinical Outcomes for Patients With Acinetobacter baumannii Bacteremia.

Gu Z, Han Y, Meng T, Zhao S, Zhao X, Gao C, Huang W.

Medicine (Baltimore). 2016 Mar;95(9):e2943. doi: 10.1097/MD.0000000000002943.


Clinical outcomes of carbapenem-resistant Acinetobacter baumannii bloodstream infections: study of a 2-state monoclonal outbreak.

Munoz-Price LS, Zembower T, Penugonda S, Schreckenberger P, Lavin MA, Welbel S, Vais D, Baig M, Mohapatra S, Quinn JP, Weinstein RA.

Infect Control Hosp Epidemiol. 2010 Oct;31(10):1057-62. doi: 10.1086/656247.


Risk factors and clinical outcomes of patients with carbapenem-resistant Acinetobacter baumannii bacteremia.

Huang ST, Chiang MC, Kuo SC, Lee YT, Chiang TH, Yang SP, Ti-Yin, Chen TL, Fung CP.

J Microbiol Immunol Infect. 2012 Oct;45(5):356-62. doi: 10.1016/j.jmii.2011.12.009. Epub 2012 May 9.


[Analysis of risk factors on prognosis of Acinetobacter baumannii bloodstream infection].

Qiao L, Zhang JS, Mei YN, Zhang HZ, Su CL.

Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2013 Aug;25(8):471-4. doi: 10.3760/cma.j.issn.2095-4352.2013.08.006. Chinese.


Multidrug Resistance Acinetobacter Bacteremia Secondary to Ventilator-Associated Pneumonia: Risk Factors and Outcome.

Brotfain E, Borer A, Koyfman L, Saidel-Odes L, Frenkel A, Gruenbaum SE, Rosenzweig V, Zlotnik A, Klein M.

J Intensive Care Med. 2017 Oct;32(9):528-534. doi: 10.1177/0885066616632193. Epub 2016 Feb 21.


Carbapenem-resistant Acinetobacter baumannii Bacteremia in Liver Transplant Recipients.

Kim YJ, Kim SI, Lee YD, Choi HJ, Choi JY, Yoon SK, You YK, Kim DG.

Transplant Proc. 2018 May;50(4):1132-1135. doi: 10.1016/j.transproceed.2018.01.043.


Supplemental Content

Support Center